|
|
Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Reno/Sparks, Nevada, June 20-25, 2009
Carmen L. Rosa, MD, Paul G. Wakim, PhD (both from the NIDA Center for the Clinical Trials Network (CCTN)).
The use of evidence-based treatments (treatment proved effective through controlled randomized clinical trials) has become the practice for substance abuse treatment programs. Randomized clinical trials provide a rigorous demonstration of effectiveness and should be used to guide policy makers and clinical programs in the adoption of evidence-based practices and treatments (EBP). The National Drug Abuse Treatment Clinical Trials Network (CTN) serves as a vehicle for providing EBP for substance abuse programs. The CTN conducts pharmacological and behavioral clinical trials with individuals seeking treatment at community treatment programs around the nation. The interventions typically studied are efficacious drug addiction treatments that are being tested for effectiveness in "real life" settings. To date, the CTN has conducted 23 clinical trials. A total of 9,681 participants have been randomized, of which 40% are women, 22% African Americans, and 19% Hispanics. The CTN tracks a number of variables critical to management and analysis of clinical trial data, including the availability of primary outcome measures, the rate of treatment exposure (sessions attended) and the proportion of follow-up assessments obtained. This poster provides data comparing gender and racial/ethnic groups with respect to four key variables: (1) CTN trial participation; (2) availability of primary outcome measures; (3) treatment exposure; and (4) follow-up assessments. (Poster, PDF, English, 2009)
 Keywords:
African Americans |
CTN research agenda |
Evidence-based treatment |
Hispanics and Latinos |
Minority groups |
National Drug Abuse Treatment Clinical Trials Network |
Women |
College on Problems of Drug Dependence (CPDD) annual meeting, 2009
Document No: 375
Submitted by Carmen Rosa, MS, CCTN (7/14/2009). |
